Day: March 19, 2026

SATO Corporation, Stock Exchange Release 19 March 2026 at 2:45 pm The Annual General Meeting of SATO Corporation was held on 19 March 2026 in Helsinki. The meeting approved the financial statements for 2025 and granted discharge from liability to the Board of Directors and the CEO. The Annual General Meeting decided that a dividend of EUR 0.25 per share be paid for the financial year 2025 and approved the proposals of the Shareholders’ Nomination Committee regarding the members of the Board of Directors and their remuneration. In addition, the meeting authorised the Board of Directors to decide on the issuance of shares. Adoption of financial statements and discharge from liability The Annual General Meeting approved the financial statements for 2025 and granted discharge from liability to the members of the Board of Directors and...

Jade DragonJade DragonMACAU, March 19, 2026 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment has once again solidified its position as a global leader in fine dining, leading Macau in MICHELIN Guide Hong Kong & Macau 2026 with eight MICHELIN Stars across five of its restaurants located in City of Dreams, Studio City and Altira Macau. City of Dreams proudly stands as Macau’s premier gastronomic destination, holding six MICHELIN Stars, the most of any integrated resort in the city. Unveiled today at the esteemed guide’s 18th edition ceremony, this year’s results see City of Dreams’ Cantonese fine dining restaurant Jade Dragon retain its notable Three MICHELIN Star status for the eighth consecutive year, and Alain Ducasse at Morpheus granted Two MICHELIN Stars for the eighth consecutive year. Additionally,...

Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, March 19, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today reported financial results for the year ended December 31, 2025 and provided a clinical update highlighting rapid progress toward a major upcoming milestone in its pivotal MIRACLE trial of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML). “With the MIRACLE trial rapidly progressing and the first MIRACLE interim readout now clearly within reach, we believe 2026 will be a defining year for Moleculin,” said Walter Klemp, Chairman and CEO of Moleculin....

New Counterpart Health whitepaper finds patients whose primary care physicians (PCP) used Counterpart Assistant’s flu-related clinical insight were 1.89 times more likely to receive a flu vaccination — and patients with COPD and CHF experienced significantly fewer flu-related hospitalizations and emergency visits SAN FRANCISCO, March 19, 2026 (GLOBE NEWSWIRE) — Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), and a leading AI-powered physician-enablement platform today released a whitepaper titled “Driving Clinical Excellence in Chronic Disease: Counterpart Assistant’s Role in Flu Preventative Care.” The analysis examines the role of CA’s real-time clinical insights on immunization rates and flu-related acute care...

Sets Stage for Next Phase of Growth Boca Raton, Fla. , March 19, 2026 (GLOBE NEWSWIRE) — Powell Max Limited (Nasdaq: PMAX) (“Powell Max” or the “Company”), a financial communications services provider, today announced it has engaged RBW Capital Partners LLC (“RBW”) and Spartan Capital Securities, LLC (“Spartan”) to provide certain financial advisory and financial placement agency and investment banking services to Powell Max Ltd. The Securities and Brokerage Services are offered through Spartan and Dawson James Securities, Inc.  Powell Max engaged RBW and Spartan as exclusive agents to the Company in connection with evaluating, structuring, and executing potential strategic transactions. RBW and Spartan will provide strategic and financial advice to the Company, but will not be responsible for providing legal, accounting, tax,...

ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Thursday, March 26, 2026. The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from 2025. About Quoin Pharmaceuticals Ltd.Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to...

The Future of Outdoor LivingOutdoor living isn’t just a trend for 2026, it’s a priority. According to the latest Outdoor Living Trend Report from the International Casual Furnishings Association, 77% of U.S. homeowners say they wish they spent more time outside, and nearly 60% plan to invest in their outdoor spaces this year, with durability and practicality topping their wish lists.WINCHESTER, Va., March 19, 2026 (GLOBE NEWSWIRE) — Outdoor living isn’t just a trend for 2026, it’s a priority. According to the latest Outdoor Living Trend Report from the International Casual Furnishings Association, 77% of U.S. homeowners say they wish they spent more time outside, and nearly 60% plan to invest in their outdoor spaces this year, with durability and practicality topping their wish lists. “Homeowners want outdoor spaces that...

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The offering was led by a new life science dedicated investor and a long-only mutual fund  DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a securities purchase agreement with several new institutional investors for the purchase and sale of 25,000,000 shares of common stock pursuant to a registered direct offering. The offering was led by a new life science dedicated investor and a long-only mutual fund. The gross...

Will enable creators and brands to turn live content into seamless, interactive shopping experiences NEWPORT BEACH, Calif., March 19, 2026 (GLOBE NEWSWIRE) — Amaze Holdings, Inc. (NYSE American: AMZE) (“Amaze” or the “Company”) today announced expanded live shopping capabilities designed to help creators and brands convert audience engagement into immediate sales will be available in the coming months. Amaze’s live shopping capabilities will allow creators and brands to seamlessly integrate commerce into live video, enabling them to create meaningful connections with fans at any time . As product discovery increasingly happens through content, Amaze’s live shopping capabilities will move beyond traditional e-commerce by integrating live video, and convert passive viewers into active customers. “Creators have become the most powerful...